首页|期刊导航|Pharmacoeconomics and Policy|Disease burden and productivity loss of T2DM in the Western Pacific region from 1990 to 2050:A modeling study using GBD 2021

Disease burden and productivity loss of T2DM in the Western Pacific region from 1990 to 2050:A modeling study using GBD 2021OA

中文摘要

Type 2 diabetes mellitus(T2DM)exhibits a notably high prevalence across the Western Pacific region,resulting in considerable disease burden and substantial productivity losses.Accordingly,the present study investigated the disease burden and associated productivity losses attributable to T2DM among adults,while also forecasting the disease burden through 2050.This investigation adopted a quantitative approach and drew upon datasets obtained from the Global Burden of Disease(GBD)2021 database,the World Bank,the United Nations,and the International Labor Organization.The burden of disease was quantified using disability‑adjusted life years(DALYs),whereas productivity losses were calculated through the human capital method.Future disease burden was projected by employing a Bayesian age‑period‑cohort(BAPC)model.In 2021,the age‑standardized DALYs rate(ASDR)in the region reached 624.55 per 100,000 population,with Fiji recording the greatest burden and Australia the smallest.From 1990 to 2021,the overall disease burden followed an increasing trajectory accompanied by fluctuations.Projections based on the BAPC model indicate that the ASDR will rise to 2243.12 per 100,000 population by 2050.The estimated annual productivity loss attributable to T2DM in the region exceeds 220 billion U.S.dollars(USD).China showed a marked increase in productivity loss over the study period.Japan reported the highest absolute losses,but the growth in these losses leveled off after 2010.Emerging economies showed accelerating increases in productivity loss,whereas small island states showed substantial variability.Over the past three decades,the disease burden and productivity loss from T2DM in the Western Pacific region have increased,and projections indicate that this upward trend will continue.Comprehensive and sustainable interventions,including health policies,educational initiatives,and social protection measures,are needed to reduce disparities associated with T2DM.

Luyou Dong;Dachuang Zhou;Wenxi Tang

Department of Infectious Disease and Public Health,City University of Hong Kong,Hong Kong SAR 999077,ChinaSchool of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,ChinaSchool of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China

医药卫生

Type 2 diabetes mellitusDisease burdenProductivity lossPredictionTrend

《Pharmacoeconomics and Policy》 2026 (1)

P.12-18,7

10.1016/j.pharp.2026.03.001

评论